One up, one down for CSL

Posted 6 April 2021 PM

CSL's acquisition of a one dose haemophilia B therapy from Dutch biotech UniQure appears set to pay off after a cancer scare around the program was effectively quashed.

According to UniQure, an independent investigation into a case of hepatocellular carcinoma (HCC) diagnosed in one patient in the HOPE-B pivotal trial found it was "highly unlikely" there was a link to its treatment etranacogene dezaparvovec (AMT-061).

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here